{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:00:13Z","timestamp":1793412013248,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Hamburg-Eppendorf (UKE)","id":[{"id":"https:\/\/ror.org\/01zgy1s35","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Within a universal healthcare system, the prognostic influence of socioeconomic status (SES) on survival in follicular lymphoma (FL) remains unclear. Thus, we conducted a nationwide, population-based analysis linking cancer registry data with regional SES indicators. Data from patients diagnosed with FL between 2013 and 2023 with mortality follow-up until the end of 2024 were obtained from the German Center for Cancer Registry and linked to the German Index of Socioeconomic Deprivation (GISD) at the district level, which comprises indicators of education, employment, and income. The primary endpoint was relative survival (RS) and secondary endpoint overall survival (OS), comparing patients from low-, middle-, and high-SES districts (categories based on official GISD quintiles). In total, 36 622 FL patients from 400 districts were included. At five years about 80% in female patients and about 77% in male patients were alive. After adjustment for baseline characteristics, females and males in high-SES districts had a 16% and 19% lower excess mortality risk than those in low-SES districts. Further adjustment for degree of urbanity, access to certified centers and a proxy for health-related lifestyle and comorbidities attenuated these differentials considerably. In this first study in a universal healthcare context, SES was an important determinant of survival among FL patients. Proxies for degree of urbanity, access to healthcare and comorbidity at the district-level appeared to account for a substantial part of these differences.<\/jats:p>","DOI":"10.1038\/s41598-026-68993-7","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T15:24:27Z","timestamp":1789485867000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Socioeconomic disparities in survival among follicular lymphoma patients"],"prefix":"10.1038","volume":"16","author":[{"given":"Susanne","family":"von Kroge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Bokemeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"von dem Knesebeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Tetzlaff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Nennecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemarie","family":"Schultz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Kusche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"68993_CR1","unstructured":"Follicular Lymphoma \u2014 Cancer Stat Facts. https:\/\/seer.cancer.gov\/statfacts\/html\/follicular.html (Accessed 7 Sep 2025)."},{"key":"68993_CR2","unstructured":"Follikul\u00e4res, L. \u2014 Onkopedia. https:\/\/www.onkopedia.com\/de\/onkopedia\/guidelines\/follikulaeres-lymphom\/@@guideline\/html\/index.html (Accessed 7 Sep 2025)."},{"key":"68993_CR3","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s00761-025-01721-4","volume":"31","author":"A Schultz","year":"2025","unstructured":"Schultz, A., Ghandili, S., Kim-Wanner, S. Z., Neuser, P. & Peters, F. Fact sheet: epidemiology of non-Hodgkin lymphoma in Germany from 2013 to 2022. Onkologie 31, 525\u2013534 (2025).","journal-title":"Onkologie"},{"key":"68993_CR4","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","volume":"104","author":"P Solal-C\u00e9ligny","year":"2004","unstructured":"Solal-C\u00e9ligny, P. et al. Follicular lymphoma international prognostic index. Blood 104, 1258\u20131265 (2004).","journal-title":"Blood"},{"key":"68993_CR5","doi-asserted-by":"publisher","unstructured":"Sperlich, S., Beller, J., Safieddine, B., Tetzlaff, J. & Geyer, S. Widening Educational Inequalities in Physical Health Due to the Obesity Trend?-A Mediation Analysis Using the German Socio-Economic Panel Study. Int. J. Public. Health. 69, https:\/\/doi.org\/10.3389\/IJPH.2024.1606932 (2024).","DOI":"10.3389\/IJPH.2024.1606932"},{"key":"68993_CR6","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s00391-018-01487-y","volume":"52","author":"T Lampert","year":"2019","unstructured":"Lampert, T. & Hoebel, J. [Socioeconomic inequalities in health in later life]. Z. Gerontol. Geriatr. 52, 91\u201399 (2019).","journal-title":"Z. Gerontol. Geriatr."},{"key":"68993_CR7","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1136\/jech-2018-210941","volume":"73","author":"AC Clause-Verdreau","year":"2019","unstructured":"Clause-Verdreau, A. C., Audureau, \u00c9., Lepl\u00e8ge, A. & Coste, J. Contrasted trends in health-related quality of life across gender, age categories and work status in France, 1995\u20132016: repeated population-based cross-sectional surveys using the SF-36. J. Epidemiol. Community Health (1978). 73, 65\u201372 (2019).","journal-title":"J. Epidemiol. Community Health (1978)"},{"key":"68993_CR8","doi-asserted-by":"publisher","unstructured":"Jansen, L. et al. Socioeconomic deprivation and cancer survival in a metropolitan area: An analysis of cancer registry data from Hamburg, Germany. Lancet Reg. Health - Europe. 4, https:\/\/doi.org\/10.1016\/j.lanepe.2021.100063 (2021).","DOI":"10.1016\/j.lanepe.2021.100063"},{"key":"68993_CR9","doi-asserted-by":"crossref","unstructured":"Tetzlaff, F. et al. Widening area-based socioeconomic inequalities in cancer mortality in Germany between 2003 and 2019. Scientific Reports. 13, 1\u201311 (2023).","DOI":"10.1038\/s41598-023-45254-5"},{"key":"68993_CR10","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1002\/ijc.34662","volume":"153","author":"L Jansen","year":"2023","unstructured":"Jansen, L. et al. Trends in cancer incidence by socioeconomic deprivation in Germany in 2007 to 2018: An ecological registry-based study. Int. J. Cancer. 153, 1784\u20131796 (2023).","journal-title":"Int. J. Cancer"},{"key":"68993_CR11","doi-asserted-by":"publisher","unstructured":"Ghandili, S., Dierlamm, J., Bokemeyer, C., Kusche, H. & Peters, F. A German perspective on the impact of socioeconomic status in diffuse large B-cell lymphoma. Blood Cancer J. 14, https:\/\/doi.org\/10.1038\/S41408-024-01158-9 (2024).","DOI":"10.1038\/S41408-024-01158-9"},{"key":"68993_CR12","doi-asserted-by":"publisher","unstructured":"Smith, M. J. et al. Excess Mortality by Multimorbidity, Socioeconomic, and Healthcare Factors, amongst Patients Diagnosed with Diffuse Large B-Cell or Follicular Lymphoma in England. Cancers (Basel). 13, https:\/\/doi.org\/10.3390\/CANCERS13225805 (2021).","DOI":"10.3390\/CANCERS13225805"},{"key":"68993_CR13","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1080\/10428194.2018.1546855","volume":"60","author":"AJ Ritter","year":"2019","unstructured":"Ritter, A. J., Goldstein, J. S., Ayers, A. A. & Flowers, C. R. Rural and urban patients with diffuse large B-cell and follicular lymphoma experience reduced overall survival: A National Cancer DataBase study. Leuk. Lymphoma. 60, 1656 (2019).","journal-title":"Leuk. Lymphoma"},{"key":"68993_CR14","doi-asserted-by":"publisher","unstructured":"Smith, M. J., Rachet, B. & Luque-Fernandez, M. A. Mediating Effects of Diagnostic Route on the Comorbidity Gap in Survival of Patients with Diffuse Large B-Cell or Follicular Lymphoma in England. Cancers (Basel). 14, https:\/\/doi.org\/10.3390\/CANCERS14205082 (2022).","DOI":"10.3390\/CANCERS14205082"},{"key":"68993_CR15","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.1200\/JCO.2008.18.8052","volume":"27","author":"THM Keegan","year":"2009","unstructured":"Keegan, T. H. M., McClure, L. A., Foran, J. M. & Clarke, C. A. Improvements in survival after follicular lymphoma by race\/ethnicity and socioeconomic status: a population-based study. J. Clin. Oncol. 27, 3044\u20133051 (2009).","journal-title":"J. Clin. Oncol."},{"key":"68993_CR16","doi-asserted-by":"publisher","first-page":"743","DOI":"10.3109\/10428194.2012.727415","volume":"54","author":"THM Keegan","year":"2013","unstructured":"Keegan, T. H. M. et al. Rituximab use and survival after diffuse large B-cell or follicular lymphoma: a population-based study. Leuk. Lymphoma. 54, 743\u2013751 (2013).","journal-title":"Leuk. Lymphoma"},{"key":"68993_CR17","doi-asserted-by":"publisher","first-page":"e18173","DOI":"10.1200\/JCO.2019.37.15_suppl.e18173","volume":"37","author":"RS Sheppard","year":"2019","unstructured":"Sheppard, R. S., Adekunle, A., Beale, S. & Ahluwalia, M. Racial and socioeconomic disparities in follicular lymphoma survival. J. Clin. Oncol. 37, e18173\u2013e18173 (2019).","journal-title":"J. Clin. Oncol."},{"key":"68993_CR18","doi-asserted-by":"publisher","unstructured":"Smith, M. J. et al. Association between multimorbidity and socioeconomic deprivation on short-term mortality among patients with diffuse large B-cell or follicular lymphoma in England: a nationwide cohort study. BMJ Open. 11, https:\/\/doi.org\/10.1136\/BMJOPEN-2021-049087 (2021).","DOI":"10.1136\/BMJOPEN-2021-049087"},{"key":"68993_CR19","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1002\/ajh.23708","volume":"89","author":"C Nabhan","year":"2014","unstructured":"Nabhan, C. et al. The impact of race, age, and sex in follicular lymphoma: A comprehensive SEER analysis across consecutive treatment eras. Am. J. Hematol. 89, 633\u2013638 (2014).","journal-title":"Am. J. Hematol."},{"key":"68993_CR20","doi-asserted-by":"publisher","first-page":"3825","DOI":"10.1182\/bloodadvances.2023011040","volume":"8","author":"C Nze","year":"2024","unstructured":"Nze, C. et al. Impact of patient demographics and neighborhood socioeconomic variables on clinical trial participation patterns for NHL. Blood Adv. 8, 3825\u20133837 (2024).","journal-title":"Blood Adv."},{"key":"68993_CR21","doi-asserted-by":"publisher","first-page":"4616","DOI":"10.1182\/bloodadvances.2024013633","volume":"8","author":"WB Fingrut","year":"2024","unstructured":"Fingrut, W. B. et al. The American Society of Hematology Health Equity Compendium: examining health equity across the Blood journals. Blood Adv. 8, 4616\u20134624 (2024).","journal-title":"Blood Adv."},{"key":"68993_CR22","unstructured":"INKAR - BBSR. https:\/\/www.inkar.de (Accessed 11 Oct 2025)."},{"key":"68993_CR23","first-page":"2","volume":"7","author":"N Michalski","year":"2022","unstructured":"Michalski, N. et al. German Index of Socioeconomic Deprivation (GISD): Revision, update and applications. J. health Monit. 7, 2 (2022).","journal-title":"J. health Monit."},{"key":"68993_CR24","doi-asserted-by":"publisher","first-page":"2","DOI":"10.5281\/ZENODO.6840304","volume":"7","author":"N Michalski","year":"2022","unstructured":"Michalski, N., Reis, M., Tetzlaff, F., Nowossadeck, E. & Hoebel, J. German Index of Socioeconomic Deprivation (GISD). https:\/\/doi.org\/10.5281\/ZENODO.6840304","journal-title":"J. health Monit."},{"key":"68993_CR25","unstructured":"OncoMap - Liste der zertifizierten Krebszentren. http:\/\/www.oncomap.de\/centers?showMap=1 (Accessed 7 Sep 2025)."},{"key":"68993_CR26","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1093\/ije\/dyv105","volume":"44","author":"M Barbieri","year":"2015","unstructured":"Barbieri, M. et al. Data Resource Profile: The Human Mortality Database (HMD). Int. J. Epidemiol. 44, 1549\u20131556 (2015).","journal-title":"Int. J. Epidemiol."},{"key":"68993_CR27","doi-asserted-by":"publisher","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","volume":"117","author":"E Campo","year":"2011","unstructured":"Campo, E. et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 117, 5019\u20135032 (2011).","journal-title":"Blood"},{"key":"68993_CR28","doi-asserted-by":"publisher","unstructured":"Tetzlaff, F. et al. Widening socioeconomic inequalities in cancer incidence and related potential to reduce cancer between 2008 and 2019 in Germany. Sci. Rep. 15, https:\/\/doi.org\/10.1038\/S41598-025-17859-5 (2025).","DOI":"10.1038\/S41598-025-17859-5"},{"key":"68993_CR29","doi-asserted-by":"publisher","unstructured":"Pohar Perme, M., de Wreede, L. C. & Manevski, D. What is relative survival and what is its role in haematology? Best Pract. Res. Clin. Haematol. 36 https:\/\/doi.org\/10.1016\/J.BEHA.2023.101474 (2023).","DOI":"10.1016\/J.BEHA.2023.101474"},{"key":"68993_CR30","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","volume":"370","author":"E von Elm","year":"2007","unstructured":"von Elm, E. et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 370, 1453\u20131457 (2007).","journal-title":"Lancet"},{"key":"68993_CR31","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1080\/00031305.2016.1154108","volume":"70","author":"RL Wasserstein","year":"2016","unstructured":"Wasserstein, R. L. & Lazar, N. A. The ASA Statement on p-Values: Context, Process, and Purpose. Am. Stat. 70, 129\u2013133 (2016).","journal-title":"Am. Stat."},{"key":"68993_CR32","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","volume":"377","author":"G Salles","year":"2011","unstructured":"Salles, G. et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): A phase 3, randomised controlled trial. Lancet 377, 42\u201351 (2011).","journal-title":"Lancet"},{"key":"68993_CR33","doi-asserted-by":"publisher","first-page":"e160","DOI":"10.1097\/HS9.0000000000000160","volume":"2","author":"K Herfarth","year":"2018","unstructured":"Herfarth, K. et al. Rituximab With Involved Field Irradiation for Early-stage Nodal Follicular Lymphoma: Results of the MIR Study. Hemasphere 2, e160 (2018).","journal-title":"Hemasphere"},{"key":"68993_CR34","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","volume":"377","author":"R Marcus","year":"2017","unstructured":"Marcus, R. et al. Obinutuzumab for the First-Line Treatment of Follicular Lymphoma. N. Engl. J. Med. 377, 1331\u20131344 (2017).","journal-title":"N. Engl. J. Med."},{"key":"68993_CR35","unstructured":"World health statistics 2025. https:\/\/www.who.int\/data\/gho\/whs-annex (Accessed 14 Oc t2025)."},{"key":"68993_CR36","unstructured":"Musgrove, P. et al. WHO Library Cataloguing in Publication Data The principal writers of this report were. The World Health Report (2000)."},{"key":"68993_CR37","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1182\/blood-2018-03-839035","volume":"132","author":"JS Goldstein","year":"2018","unstructured":"Goldstein, J. S. et al. Disparities in survival by insurance status in follicular lymphoma. Blood 132, 1159\u20131166 (2018).","journal-title":"Blood"},{"key":"68993_CR38","first-page":"647","volume":"120","author":"J Schmitt","year":"2023","unstructured":"Schmitt, J. et al. Initial Cancer Treatment in Certified Versus Non-Certified Hospitals. Dtsch. Arztebl Int. 120, 647\u2013654 (2023).","journal-title":"Dtsch. Arztebl Int."},{"key":"68993_CR39","first-page":"645","volume":"120","author":"A Stang","year":"2023","unstructured":"Stang, A. Evaluability of the Effect of Oncology Center Certification. Dtsch. Arztebl Int. 120, 645\u2013646 (2023).","journal-title":"Dtsch. Arztebl Int."},{"key":"68993_CR40","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2147\/CLEP.S47150","volume":"5","author":"M S\u00f8gaard","year":"2013","unstructured":"S\u00f8gaard, M., Thomsen, R. W., Bossen, K. S., S\u00f8rensen, H. T. & N\u00f8rgaard, M. The impact of comorbidity on cancer survival: a review. Clin. Epidemiol. 5, 3\u201329 (2013).","journal-title":"Clin. Epidemiol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-68993-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-68993-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-68993-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T15:41:35Z","timestamp":1789486895000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-68993-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["68993"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-68993-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]},"assertion":[{"value":"19 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"28763"}}